Suicides in National Hormone Pituitary Program Recipients of Cadaver-Derived Human Growth Hormone
Published by Oxford University Press on behalf of the Endocrine Society 2023..
Context: Numerous reports of suicide among individuals who received cadaver-derived human growth hormone (c-hGH) through the National Hormone Pituitary Program (NHPP) raised the alarm for potentially increased suicide risk.
Objective: We conducted a study to assess suicide risk in the NHPP cohort and identify contributing factors to facilitate early recognition and intervention.
Methods: The study population consisted of patients receiving NHPP c-hGH starting from 1957, and cohort deaths with an ICD code consistent with suicide or possible suicide through 2020 were evaluated. Descriptive data were extracted from medical records. Standardized mortality ratios (SMRs) to compare the observed number of suicide deaths in the cohort to the expected number were calculated using general population suicide rates by sex, age group, and time period.
Results: Among 6272 patients there were 1200 all-cause cohort deaths, of which 55 (52 male, 3 female) were attributed to suicide. Of these, 47 were identified by ICD code alone compared to an expected count of 37.8 (SMR = 1.25, 95% CI 0.91-1.66). Among male cohort members, the SMR was 1.33 (95% CI 0.97-1.78). Elevated risk of suicide was detected for cohort members aged 25-34 (SMR = 1.79, 95% CI 1.06-2.83) and during the period from September 19, 1985, to December 31, 1998 (SMR = 1.70, 95% CI 1.02-2.65).
Conclusion: Overall, the observed number of suicides among NHPP c-hGH recipients was not significantly higher than expected. However, certain subgroups may be at elevated risk of suicide. Studies are needed to better understand the nature and magnitude of suicide risk among c-hGH recipients to facilitate early intervention to prevent suicide deaths.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Journal of the Endocrine Society - 7(2023), 12 vom: 02. Nov., Seite bvad130 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abrams, Joseph Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Human growth hormone |
|---|
| Anmerkungen: |
Date Revised 05.12.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1210/jendso/bvad130 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365157910 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365157910 | ||
| 003 | DE-627 | ||
| 005 | 20231226101057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/jendso/bvad130 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1217.xml |
| 035 | |a (DE-627)NLM365157910 | ||
| 035 | |a (NLM)38024647 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abrams, Joseph Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Suicides in National Hormone Pituitary Program Recipients of Cadaver-Derived Human Growth Hormone |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Published by Oxford University Press on behalf of the Endocrine Society 2023. | ||
| 520 | |a Context: Numerous reports of suicide among individuals who received cadaver-derived human growth hormone (c-hGH) through the National Hormone Pituitary Program (NHPP) raised the alarm for potentially increased suicide risk | ||
| 520 | |a Objective: We conducted a study to assess suicide risk in the NHPP cohort and identify contributing factors to facilitate early recognition and intervention | ||
| 520 | |a Methods: The study population consisted of patients receiving NHPP c-hGH starting from 1957, and cohort deaths with an ICD code consistent with suicide or possible suicide through 2020 were evaluated. Descriptive data were extracted from medical records. Standardized mortality ratios (SMRs) to compare the observed number of suicide deaths in the cohort to the expected number were calculated using general population suicide rates by sex, age group, and time period | ||
| 520 | |a Results: Among 6272 patients there were 1200 all-cause cohort deaths, of which 55 (52 male, 3 female) were attributed to suicide. Of these, 47 were identified by ICD code alone compared to an expected count of 37.8 (SMR = 1.25, 95% CI 0.91-1.66). Among male cohort members, the SMR was 1.33 (95% CI 0.97-1.78). Elevated risk of suicide was detected for cohort members aged 25-34 (SMR = 1.79, 95% CI 1.06-2.83) and during the period from September 19, 1985, to December 31, 1998 (SMR = 1.70, 95% CI 1.02-2.65) | ||
| 520 | |a Conclusion: Overall, the observed number of suicides among NHPP c-hGH recipients was not significantly higher than expected. However, certain subgroups may be at elevated risk of suicide. Studies are needed to better understand the nature and magnitude of suicide risk among c-hGH recipients to facilitate early intervention to prevent suicide deaths | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a US cohort study | |
| 650 | 4 | |a human growth hormone | |
| 650 | 4 | |a pituitary growth hormone | |
| 650 | 4 | |a short stature | |
| 650 | 4 | |a suicide | |
| 700 | 1 | |a Mills, James L |e verfasserin |4 aut | |
| 700 | 1 | |a Schonberger, Lawrence B |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, David |e verfasserin |4 aut | |
| 700 | 1 | |a Maddox, Ryan A |e verfasserin |4 aut | |
| 700 | 1 | |a Belay, Ermias D |e verfasserin |4 aut | |
| 700 | 1 | |a Leschek, Ellen W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Endocrine Society |d 2017 |g 7(2023), 12 vom: 02. Nov., Seite bvad130 |w (DE-627)NLM272607959 |x 2472-1972 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:12 |g day:02 |g month:11 |g pages:bvad130 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/jendso/bvad130 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 12 |b 02 |c 11 |h bvad130 | ||